Literature DB >> 2506174

Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA.

E G Levin1, K R Marotti, L Santell.   

Abstract

Tumor-promoting phorbol esters stimulate tissue plasminogen activator (tPA) release from human endothelial cells, and simultaneous elevation of cyclic AMP potentiates this response 5-fold (Santell, L., and Levin, E. G. (1988) J. Biol. Chem. 263, 16802-16808). A similar effect on tPA mRNA was observed, with phorbol myristate acetate inducing a 3.5-fold increase in steady state tPA mRNA levels and forskolin enhancing that increase to 25-fold. Peak levels occurred at 8 h after agonist addition and returned to baseline levels by 16 h. As was found with tPA antigen secretion, delayed addition of forskolin reduced the level of potentiation, and, at 6 h after phorbol 12-myristate 13-acetate (PMA), forskolin was no longer effective. The protein synthesis inhibitor cycloheximide did not inhibit the rise in tPA mRNA levels in response to PMA/forskolin nor the decline in mRNA levels between 8 and 12 h. However, peak levels (8 h) were approximately 1.5-fold higher than in cultures not treated with cycloheximide. The effect of two inhibitors of protein kinases, H-7 and staurosporine, on PMA-induced tPA antigen secretion and tPA mRNA levels were examined. H-7 and staurosporine inhibited PMA, and PMA/forskolin induced tPA secretion in a dose-dependent manner. This effect was time-dependent; the inhibitory effect was reduced with delayed H-7 addition, and, by 6 h after PMA treatment, no inhibition was observed. H-7 and staurosporine also inhibited the PMA/forskolin-induced increase in tPA mRNA levels and were less effective the later they were added. The same time-dependent effect on the potentiation of PMA-induced tPA mRNA levels by forskolin was observed. Again, delayed addition reduced the effect, and, by 6 h, potentiation was absent. The results of this study indicate that changes in mRNA levels in response to PMA and PMA/forskolin precede and determine those that occur to tPA antigen secretion. In addition, the maximal response is dependent upon the prolonged activation of an H-7- and cAMP-sensitive pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506174

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  The endothelium: physiological functions and role in microcirculatory failure during severe sepsis.

Authors:  H Ait-Oufella; E Maury; S Lehoux; B Guidet; G Offenstadt
Journal:  Intensive Care Med       Date:  2010-05-05       Impact factor: 17.440

Review 2.  The endothelial cell annexin A2 system and vascular fibrinolysis.

Authors:  MaryAnn Dassah; Arun B Deora; Kaili He; Katherine A Hajjar
Journal:  Gen Physiol Biophys       Date:  2009       Impact factor: 1.512

3.  Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro.

Authors:  J Arts; I Herr; M Lansink; P Angel; T Kooistra
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

4.  Identification of a protein transiently phosphorylated by activators of endothelial cell function as the heat-shock protein HSP27. A possible role for protein kinase C.

Authors:  L Santell; N S Bartfeld; E G Levin
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

Review 5.  Endothelial Activation and Microcirculatory Disorders in Sepsis.

Authors:  Lisa Raia; Lara Zafrani
Journal:  Front Med (Lausanne)       Date:  2022-06-03

6.  Stimulation of tissue plasminogen activator production by retinoic acid: synergistic effect on protein kinase C-mediated activation.

Authors:  R D Medh; L Santell; E G Levin
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

7.  Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester.

Authors:  R Hanemaaijer; P Koolwijk; L le Clercq; W J de Vree; V W van Hinsbergh
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

8.  Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.

Authors:  Greta L Hoetzer; Brian L Stauffer; Heather M Irmiger; Marilyn Ng; Derek T Smith; Christopher A DeSouza
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

9.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.

Authors:  Mathieu Lemaire; Véronique Frémeaux-Bacchi; Franz Schaefer; Murim Choi; Wai Ho Tang; Moglie Le Quintrec; Fadi Fakhouri; Sophie Taque; François Nobili; Frank Martinez; Weizhen Ji; John D Overton; Shrikant M Mane; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Denis Morin; Georges Deschenes; Véronique Baudouin; Brigitte Llanas; Laure Collard; Mohammed A Majid; Eva Simkova; Peter Nürnberg; Nathalie Rioux-Leclerc; Gilbert W Moeckel; Marie Claire Gubler; John Hwa; Chantal Loirat; Richard P Lifton
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 41.307

10.  Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors.

Authors:  María D Valls; María Soldado; Jorge Arasa; Miguel Perez-Aso; Adrienne J Williams; Bruce N Cronstein; M Antonia Noguera; M Carmen Terencio; M Carmen Montesinos
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.